per-SVR
In 2016, the MOH tasked the BC-CfE with evaluating health outcomes associated with direct acting antivirals (DAAs) and to identify the population at greatest risk for re-infection in order to understand the larger context driving the overall social and economic costs of HCV infection in BC, crucial steps to ultimately STOP Hepatitis®. To this end, the preservation of sustained virologic response (Per-SVR) study was developed. Per-SVR is Prospective clinical cohort of people recently completed DAAs and achieved sustained virologic response (SVR).
Study Outcomes
- rate of reinfection
- health care utilization patterns
- harm reduction engagement
- impacts of treatment on health outcomes over time
Activities
- At each study visit, UDS & blood sample (HIV, HCV) taken
- A qualitative sub-study to understand health care experiences of participants who have experienced an HCV reinfection was launched September 2021
POSTER
PUBLICATIONS
-
Beyond direct-acting antiviral therapy: Characterizing mental health conditions and depressive symptoms among patients recently treated for hepatitis C
PLOS One - 2026 -
Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy
PLOS One - 2022
